12-Hydroxyibogamine, also known as ibogaine, is a naturally occurring indole alkaloid primarily isolated from the root bark of the African shrub *Tabernanthe iboga*. It is a complex polycyclic molecule containing an isoquinuclidine core fused with an indole ring system. Ibogaine is a psychoactive substance that has been extensively studied for its potential in treating substance use disorders, particularly opioid and stimulant addiction. Its proposed mechanism of action is complex and not fully understood, but it is believed to involve multiple neurotransmitter systems. It acts as an NMDA receptor antagonist and modulates serotonin (5-HT2A/2C receptors) and dopamine systems. Its metabolite, noribogaine, is also pharmacologically active and contributes to its long-lasting effects. Research focuses on its ability to reduce withdrawal symptoms and craving, potentially "resetting" addiction-related neural pathways. Due to its significant psychoactive and physiological effects, including potential cardiotoxicity (QT prolongation) and neurotoxicity, ibogaine is classified as a Schedule I controlled substance in the United States and is strictly regulated in many countries. Its clinical use remains experimental and is typically conducted in specialized, supervised settings outside mainstream medicine. It is a prototypical example of a plant-derived compound with profound effects on the central nervous system.